A new prognostic model for FIGO stage 1 epithelial ovarian cancer

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 607-611

  Obermair, Andreas ^a   Fuller, Arlan ^b   Lopez Varela, Elisa ^b   van Gorp, Toon ^c   Vergote, Ignace ^c   Eaton, Lynne ^d   Fowler, Jeff ^d   Quinn, Michael ^e   Hammond, Ian ^f   Marsden, Donald ^g   Proietto, Anthony ^h   Carter, Jonathan ⁱ   Davy, Margaret ^j   Tripcony, Lee ^a   Abu Rustum, Nadeem ^k  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d OHIO STATE UNIVERSITY   (United States)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

^f KING EDWARD MEMORIAL HOSPITAL   (Australia)

^g ROYAL HOSPITAL FOR WOMEN   (Australia)

^h JOHN HUNTER HOSPITAL   (Australia)

ⁱ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^j ROYAL ADELAIDE HOSPITAL   (Australia)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

CA 125; Ovarian cancer; Prognosis; Staging

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 33847003042     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.09.021     Document Type: Article

References (25)

1. Young R.C., Decker D.G., Wharton J.T., Piver M.S., Sindelar W.F., Edwards B.K., et al. Staging laparatomy in early ovarian cancer. JAMA 250 (1983) 3072-3076
2. Ozols R.F., Rubin S.C., Thomas G.M., and Robboy S.J. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., and Young R.C. (Eds). Principles and practice of gynecologic oncology. 3rd ed (2000), Lippincott Willimas & Wilkins, Philadelphia, PA 981-1057
3. Bast R.C., Klug T., John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309 (1983) 883-887
4. Rustin G.J., Nelstrop A.E., Mclean P., Brady M.F., McGuire W.P., Hoskins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according serum CA 125. J. Clin. Oncol. 14 (1996) 1545-1551
5. Rustin G.J., Nelstrop A.E., Tuxen M.K., and Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125. A North Thames Ovary Group study. Ann. Oncol. 7 (1996) 361-364
6. Ind T., Iles R., Shepherd J.H., and Chard T. Serum concentration of cancer antigen 125, placental alkaline phosphatase, cancer associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 104 (1997) 1024-1029
7. Paramasivam S., Tripcony L., Crandon A., Quinn M., Hammond I., Marsden D., et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics Stage I Epithelial Ovarian Cancer: an Australian Multicenter Study. J. Clin. Oncol. 23 (2005) 5938-5942
8. Day T.G., Gallager H.S., and Rutledge F.N. Epithelial carcinoma of the ovary. The prognostic importance of histologic grade. Natl. Cancer Inst. Monogr. 42 (1975) 15-21
9. Serov S.F., Skully R.E., and Sorbin L.H. Histological typing of ovarian tumours. In: World Health Organisation (Ed). International histological classification of tumours vol. 17 (1973), World Health Organisation, Geneva
10. Einhorn N., Sjovall K., Knapp R.C., Hall P., Scully R.E., Bast Jr. R.C., et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80 (1992) 14-18
11. Jacobs I.J., Skates S., Davies A.P., Woolas R.P., Jeyerajah A., Weidemann P., et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration. A prospective cohort study. BMJ 313 (1996) 1355-1358
12. Jacobs I., Davies A.P., Bridjes J., Stabile I., Fay T., Lower A., et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306 (1993) 1030-1034
13. 25th FIGO Annual Report. The Results of Treatment in Gynecological Cancer [Annual Report on CD_Rom]. Milano, Italy, Reed Elsevier Nederland B.V., 2003.
14. McGuire W.P. CA-125 and early ovarian cancer: does this help the clinician or further muddy the water?. J. Clin. Oncol. 23 (2005) 5862-5864 [editorial]
15. International Collaborative Ovarian Neoplasm 1 (ICON1), and European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy in Ovarian Neoplasm (EORTC-ACTION). International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J. Natl. Cancer Inst. 95 (2003) 105-112
16. Young R.C., Walton L.A., Ellenberg S.S., Homesley H.D., Wilbanks G.D., Decker D.G., et al. Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. 322 (1990) 1021-1027
17. Dembo A.J., Davy M., Stenwigg A.E., Berle E.J., Bush R.S., and Kjortstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet. Gynecol. 75 (1990) 263-273
18. Vergote I., De Brabanter J., Fyles A., Bertelsen K., Einhorn N., Sevelda P., et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 375 (2001) 176-182
19. Hernson D.E. The histologic grading of neoplasms. Arch. Pathol. Lab. Med. 112 (1988) 1091-1096
20. Russel P. Surface epithelial-stromal tumors of the ovary. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract. 4th ed (1994), Springer, New York, NY 705-782
21. Guthrie D., Davy M., and Philips P.R. A study of 656 patients with "early" ovarian cancer. Gynecol. Oncol. 17 (1984) 363-369
22. Ludescher C., Weger A.R., Lindholm J., Oefner D., Hausmanninger H., Reitsamer R., et al. Prognostic significance of tumour cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma. Int. J. Gynecol. Pathol. 9 (1990) 343-351
23. Skirnisdottir I., Seidal T., Karlsson M.G., and Sorbe B. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int. J. Oncol. 26 (2005) 177-183
24. Ho C.M., Chien T.Y., Shih B.Y., and Huang S.H. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol. Oncol. 88 (2003) 393-394
25. Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., and Hoppenau B. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian cancer Study Group (AGO-OVAR). Gynecol. Oncol. 100 (2006) 300-307